SCHEDULE: QIA discloses 0.58% stake in BioXcel

Qatar Investment Authority filed a Schedule 13G/A reporting beneficial ownership of 156,066 BioXcel Therapeutics shares (0.58%) held via Q Boost Holding LLC, including warrant shares.

Summary

• Qatar Investment Authority (QIA), via wholly owned subsidiary Q Boost Holding LLC, beneficially owns 156,066 shares of BioXcel Therapeutics, Inc. common stock.
• Ownership comprises 142,051 shares currently held and 14,015 shares issuable upon exercise of an issuer warrant.
• Percent of class is 0.58% based on 27,088,601 shares outstanding (27,074,586 outstanding as of March 26, 2026 plus 14,015 warrant shares).
• QIA has sole voting power over 156,066 shares and sole dispositive power over 156,066 shares; no shared voting or dispositive power.
• Filing is on Schedule 13G (passive), certifying the securities are not held to change or influence control.
• Corporate actions referenced: a 1-for-16 reverse stock split effective February 7, 2025, and a cashless exercise on April 28, 2025 of a warrant to purchase 156,250 shares, resulting in 142,051 issued shares after withholding 14,199 shares for the exercise price.
• Date of event requiring filing is December 31, 2025; the certification was signed March 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral: a small, passive institutional position offers modest validation but implies no strategic involvement or near-term catalyst.

Positives

• Presence of a reputable institutional investor (QIA) as a passive holder, indicating some institutional interest.
• Clear disclosure of sole voting and dispositive power (156,066 shares), reducing uncertainty about control intent.
• Warrant position is modest (14,015 shares issuable), with total beneficial ownership remaining well below 5%.

Negatives

• Stake size is small at 0.58%, implying limited potential influence or strategic involvement.
• Cashless warrant exercise (April 28, 2025) provided no cash proceeds to the issuer.

Future Outlook

No forward-looking statements or guidance are provided; the filer certifies the holdings are not for the purpose of changing or influencing control.

Management Comments

• Certification: the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that sub-1% passive positions by sovereign wealth funds in small- and mid-cap biotech issuers are common portfolio allocations and typically do not signal strategic engagement or governance changes.

Comparison to Industry Standards

• Ownership threshold: At 0.58%, QIA’s stake is well below the 5% threshold that often attracts heightened market attention; comparable passive filings by institutional holders in biotech frequently sit below 1%.
• Filing type: Use of Schedule 13G (rather than 13D) aligns with passive ownership norms among sovereign and large institutional investors.
• Control intent: The explicit non-control certification mirrors standard practice for passive institutional holders across the sector (e.g., similar disclosures by large asset managers in small-cap biotech names).

Stakeholder Impact

• Shareholders: Minimal governance impact as the holder is passive and below 1%.
• Potential marginal dilution from 14,015 warrant shares if exercised, though already included in beneficial ownership calculation.

Key Dates

Keywords

BioXcel Therapeutics, Schedule 13G/A, beneficial ownership, Qatar Investment Authority, Q Boost Holding LLC, 0.58% stake, reverse stock split, warrant exercise, biotech, BXCL